Introduction {#s1}
============

Primary biliary cirrhosis (PBC) is a chronic immune-mediated liver disease characterized by progressive intrahepatic bile-duct destruction, leading to cirrhosis and eventual liver failure \[[@B1]\]. Although the etiology of PBC is unclear, it has been suggested that both genetic and environmental factors may initiate and promote the disease \[[@B2]\]. Specifically, the high concordance for PBC in monozygotic twins, family clustering, and female predominance suggest that genetic factors may play an important role in the development of PBC \[[@B3]-[@B5]\].

Human leukocyte antigens (HLA) are encoded by genes within the major histocompatibility complex (MHC), located on chromosome 6p21. Genes located in the centromeric class II region of the *HLA* encode polymorphic *HLA-DR*, *HLA-DQ*, and *HLA-DP*, which are expressed on antigen-presenting cells and can participate in antigen processing. Although accurate mechanisms to explain how the *HLA* class *II* gene induces autoimmunity are unclear, several *HLA class II* alleles have been identified to confer genetic risk for or protection against many autoimmune diseases \[[@B6]\], and such associations between certain *HLA class II* alleles and the development of PBC have been extensively investigated.

The most commonly detected *HLA* genes involved in susceptibility to PBC are the Class II *DRB1\*08* allele family, especially *DRB1\*0801* and *DRB\*0803*, which were implicated as risk factors for PBC in some studies \[[@B7]-[@B9]\]. However, data to suggest an association between *DRB1\*08* and PBC risk are controversial at this time. In addition to PBC risk conferred by *HLA Class II* alleles, several studies suggest that some alleles could be protective against PBC such as *DRB1\*11* and *DRB1\*13* \[[@B10],[@B11]\]. These results support the concept that *HLA Class II* alleles may have diverse roles in PBC pathogenesis.

In addition to *HLA* alleles, some haplotypes, such as *DRB1\*0803-DQA1\*0103-DQB1\*0601* and *DRB1\*0801-DQA1\*0401-DQB1\*402*, were also found to be associated with PBC risk in studies of patients with diverse ethnic origins \[[@B8]-[@B10]\]. Further evidence from recent genome-wide association studies (GWAS) also revealed a strong association between polymorphisms in the *HLA II* region and PBC. In GWASs, the *HLA-DRB1* and *HLA-DQB1* locus were reported to be significantly associated with susceptibility to PBC \[[@B12],[@B13]\]. To better understand GWAS results regarding roles of *HLA* class *II* in PBC, quantitative analyses are needed to pool data and estimate associations.

Data supporting a protective role for *HLA Class II* alleles is of interest to investigators researching molecular mechanisms of PBC disease development \[[@B14]\]. Although many studies have focused on the involvement of *HLA* genes in PBC, results from these investigations were inconsistent or inconclusive due to small sample sizes. In the view of existing heterogeneity among these studies, we conducted a meta-analysis to comprehensively assess the association between *HLA Class II* and PBC risk.

Methods {#s2}
=======

Search strategy {#s2.1}
---------------

A literature search of electronic databases including PubMed, EMBASE, (updated to 22 May 2013) was conducted independently by two investigators (BDQ and JC). The search included only published studies on association between *HLA-Class II* (*HLA-DRB1*, *HLA-DQB1*, and *HLA-DPB1*) and susceptibility to PBC. The search strategies including Mesh terms and keywords were as follows: "primary biliary cirrhosis", "human leukocyte antigens", "major histocompatibility complex", and "HLA-DR/DQ/DP antigens". No limit was placed on publication language or geographic area.

Study selection {#s2.2}
---------------

Studies included in the meta-analysis fulfilled selection criteria as follows: a) the study should be a case-control design; b) PBC patients should be diagnosed according to internationally accepted criteria; c) the study should contain sufficient published data for the evaluation of an odds ratio (OR) with a 95% confidence interval (95%CI); and d) the study should have been published in journals as full articles. Studies which had one of the following exclusion were discarded: a) the study was based on family or sibling pairs; b) the study had repeated reports on the same population or subpopulation; c) the study had no control group; d) there was insufficient published data for extraction; and e) the paper was a review or abstract.

Data extraction {#s2.3}
---------------

All included studies were retrieved and the data were extracted independently in duplicate using a standard protocol by two authors (BDQ and JC). Study characteristics were extracted, including the first author, year of publication, country in which the study was launched, ethnicity of the population sample, *HLA* genotyping technique, sample size, and total number of cases and controls ([Table **1**](#pone-0079580-t001){ref-type="table"}). In the literature review, data were chiefly calculated using two methods. One method compared the difference in the number of individuals who carried *HLA-DRB1*, *HLA-DQB1*, *HLA-DPB1* alleles, comparing PBC patients and controls (***n~a~/N,n*~*a*~** is number of individuals who carried the alleles, ***N*** is the total number of PBC patients or controls). The second method used differences in the frequency of the alleles between PBC patients and controls (***n~b~/2N*, *n*~*b*~** is the number of some alleles and ***N*** is the total number of PBC patients or controls).
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###### Characteristics of 34 publications included in the meta-analysis of *HLA* class *II* and PBC susceptibility.

  Author                       Year   Country             Ethnicity                               Sample size       Number of PBC patient/control       Specific technique
  ---------------------------- ------ ------------------- --------------------------------------- ----------------- ----------------------------------- -----------------------------
  Miyamori H, et al.           1983   Japan               Asian                                   72                22/50                               microlymphocytotoxicity
  Bassendine MF, et al.        1985   UK                  Caucasian                               275               75/200                              microlymphocytotoxicity
  Johnston DE, et al.          1987   UK                  Caucasian                               200               71/129                              microlymphocytotoxicity
  Briggs DC, et al.            1987   UK                  Caucasian                               403               96/307                              microlymphocytotoxicity
  Gores GJ, et al.             1987   USA                 Caucasian                               285               114/171                             microlymphocytotoxicity
  Prochazka EJ, et al.         1990   USA                 Caucasian                               1,581             35/1,546                            microlymphocytotoxicity
  Manns MP, et al.             1991   Germany             Caucasian                               201               25/176                              microlymphocytotoxicity
  Underhill J, et al.          1992   UK                  Caucasian                               321               159/162                             PCR/RFLP
  Morling N, et al.            1992   Denmark             Caucasian                               1,227             23/1,204                            microlymphocytotoxicity
  Gregory WL, et al.           1993   UK                  Caucasian                               493               130/363                             RFLP
  Begovich, et al.             1993   USA                 Caucasian                               291               51/240                              PCR-SSO
  Seki, et al.                 1993   Japan               Asian                                   191               41/150                              microlymphocytotoxicity/PCR
  Onishi S, et al.             1994   Japan               Asian                                   246               31/215                              PCR-SSO
  Zhang L, et al.              1994   UK                  Caucasian                               83                40/43                               PCR/RFLP
  Mehal WZ, et al.             1994   USA                 Caucasian                               125               64/61                               RFLP
  Underhill JA, et al.         1995   UK                  Caucasian                               185               82/103                              PCR-SSO
  Mella JG, et al.             1995   Germany             Caucasian                               79                32/47                               PCR-SSO
  Akimoto S, et al.            1999   Japan               Asian                                   228               13/215                              NA
  Donaldson P, et al.          2001   UK                  Caucasian                               266               164/102                             PCR-SSO
  Stone J, et al.              2002   USA                 Caucasian                               370               154/216                             PCR-SSP
  Wassmuth R, et al.           2002   Germany             Caucasian                               257               99/158                              PCR-SSO
  Invernizzi P, et al.         2003   Italy               Caucasian                               670               112/558                             PCR-SSO
  Bittencourt PL, et al.       2003   Brazil              Caucasoid/African American/Amerindian   144               61/83                               PCR-SSP
  Jiang XH, et al.             2004   China               Asian                                   95                52/43                               PCR-SSP
  Mullarkey ME, et al.         2005   USA                 Caucasian                               453               72/381                              PCR-SSO
  Chen C, et al.               2005   China               Asian                                   132               72/60                               PCR-SSP
  Liu HY, et al.               2006   China               Asian                                   496               65/431                              PCR-SSP
  Donaldson PT, et al.         2006   UK/Italy            Caucasian                               823               492/331                             PCR-SSO
  Zhao J, et al.               2006   China               Asian                                   107               40/67                               PCR-SSP
  Invernizzi P, et al.         2008   Italy               Caucasian                               2,656             664/1,992                           PCR-SSO
  Vázquez-Elizondo G, et al.   2009   Mexico              Mexican/Spanish                         390               9/381                               PCR-SSP
  Nakamura M, et al.           2010   Japan               Asian                                   592               334/258                             PCR-SBT
  Chong VH, et al.             2010   Brunei Darussalam   Asian                                   74                9/65                                PCR-SSO
  Umemura T, et al.            2012   Japan               Asian                                   752               229/523                             PCR-SSO
  Total                        /      /                   /                                       14763             3732/11031                          /

Using these methods, data were pooled and a meta-analysis was performed. Any disagreement in the data was resolved by discussion and consensus (The data would be extracted independently by other authors using the same standard protocol).

Assessment of study quality {#s2.4}
---------------------------

Due to the lack of standardized quality criteria for meta-analyses of single nucleotide polymorphism studies, we chose the Newcastle-Ottawa scale (NOS) to assess the quality of these non-random studies. According to the NOS, the criteria for evaluation include selection of cases and controls, comparability of cases and controls, and ascertainment of exposure \[[@B15]\]. The scoring system provided a summary numeric score of quality that ranged from 0 star to 9 stars. The studies were graded into the three categories: high (\>=7 stars), medium (4-6 stars) and low (\<=3 stars) quality \[16\].

Statistical analysis {#s2.5}
--------------------

The final effect ORs and 95%CIs were calculated in a random-effect or fixed-effect model to evaluate the strength of the association between HLA Class II and PBC risk. Heterogeneity of effects among studies was estimated using the means of χ^2^-based Q test and I^2^ test. For the Q test, a *P* value less than 0.1 was considered to be representative of significant heterogeneity, and an I^2^ statistic represented the percentage of total variation contributed by a between-study variation that ranged from 0 to 100% \[[@B17]\]. If no significant heterogeneity was observed, a fixed-effect model was used to pool the data. Otherwise, a random-effect model was used and meta-regression analysis was used to identify the potential source of heterogeneity if sufficient studies were included. Funnel plots, Egger's test, and Begg's test were used to determine publication bias. A sensitivity analysis was performed to test data stability, and a cumulative meta-analysis was used to determine whether the strength of a relationship was stable through the repeated performance of meta-analysis whenever a new study became available for inclusion. The number or frequency of *HLA Class II* was zero in some included studies, so these zero total event studies were included to provide the most generalizable estimated ORs \[[@B18]\]. Studies with no events in both groups were excluded. All analyses were conducted in STATA 11.0 software (Stata Corp, College Station, TX). *P* values less than 0.05 were considered significant.

Results {#s3}
=======

Studies included in the meta-analysis {#s3.1}
-------------------------------------

From the initial published work search, a total of 580 non-overlapping articles were identified and screened from the previously described electronic databases. A total of 468 articles were excluded based on screening of abstracts or titles. After retrieving the full-text articles, 78 articles were excluded based on the exclusion criteria, leaving 34 relevant studies for the meta-analysis \[[@B7]-[@B11],[@B19]-[@B47]\]. ([Figure **1**](#pone-0079580-g001){ref-type="fig"})

![Flowchart of the present meta-analysis.](pone.0079580.g001){#pone-0079580-g001}

Characteristics of included studies {#s3.2}
-----------------------------------

The thirty-four studies were published between 1983 and 2012 and were comprised of 31 English-language papers and 3 Chinese-language papers, with data for 3,732 PBC patients and 11,031 controls. All 34 studies fulfilled the inclusion criteria and an OR with a 95%CI could be obtained from each study. Study information and characteristics are depicted in [Table **1**](#pone-0079580-t001){ref-type="table"}.

Assessment of study quality {#s3.3}
---------------------------

According to the scoring system given, the quality of each study was assessed and 7 studies scored 8 stars, 11 scored 7 stars, 7 scored 6 stars, 7 scored 5 stars and 2 scored 4 stars. ([Table **S1**](#pone.0079580.s005){ref-type="supplementary-material"}).

Serological HLA-DR and PBC {#s3.4}
--------------------------

A total of 13 studies contained data on serological HLA-DR from 5,400 subjects (788 cases of PBC and 4,612 controls). The meta-analyses for associations between each HLA-DR and PBC susceptibility revealed that only 6 of 16 associations were statistically significant. The serological groups HLA-DR2, DR5, DR12, DR16, and DR52a were potent protective factors against PBC, whereas DR8 was found to be a risk factor for PBC. The pooled ORs and 95%CIs were 2.82 (1.84-4.30), 0.70 (0.53-0.91), 0.55 (0.39-0.78), 0.40 (0.19-0.86), 0.21 (0.05-0.97), and 0.60 (0.38-0.95), respectively, for DR8, DR2, DR5, DR12, DR16, and DR52a. ([Figure **S1**](#pone.0079580.s002){ref-type="supplementary-material"})

There was no heterogeneity among the studies with respect to the association between DR2, DR5, DR12, DR16, and DR52a and the risk of PBC, but a high degree of heterogeneity was found to exist between DR8 and PBC risk (I^2^= 54.8%, *P* = 0.011). A subgroup meta-analysis by ethnicity indicated that a significant association was discovered in both Caucasian and Asian groups, but the Caucasian group was significantly heterogeneous. Subsequently, the cumulative meta-analysis revealed that the estimated OR and 95%CI were stable in order of year of publication and the convergence of evidence across numerous studies confirmed the strength of HLA-DR8 as a risk factor for PBC. A statistically significant association was detected as far back as 1990 \[[@B24]\] ([Figure **2**](#pone-0079580-g002){ref-type="fig"}).

![Cumulative meta-analysis of 12 studies of *HLA-DR8* and susceptibility to PBC by the Mantel-Haenszel method with the random-effect model.](pone.0079580.g002){#pone-0079580-g002}

*HLA-DQB1* alleles and PBC {#s3.5}
--------------------------

A total of 14 meta-analyses of studies of *HLA-DQB1* alleles and PBC susceptibility were conducted. *HLA-DQB1* (*\*02*, *\*04*, *\*0401*, *\*0402* and *\*0601*) were found to be risk factors for PBC, and the pooled ORs and 95%CI were 1.40 (1.00--1.97), 2.24 (1.46--3.46), 1.41 (1.07--1.85), 3.47 (2.35--5.13), and 1.99 (1.57--2.53), respectively ([Figure **S2**](#pone.0079580.s003){ref-type="supplementary-material"}). In contrast, *HLA-DQB1* (\*0301, \*06, \*0602 and \*0604) were protective factors, and the pooled ORs and 95%CIs were 0.62 (0.48--0.79) and 0.48 (0.35--0.68), 0.58 (0.39--0.85), 0.61 (0.42--0.87), and 0.53 (0.37--0.75), 0.3 (0.18--0.58), respectively ([Figure **S3**](#pone.0079580.s004){ref-type="supplementary-material"}). No significant heterogeneity was observed in the meta-analysis for these alleles.

*HLA-DPB1* alleles and PBC {#s3.6}
--------------------------

A total of 13 meta-analyses have been conducted, but no statistically significant association between *HLA-DPB1* alleles and PBC risk was observed (data not shown).

*HLA-DRB1* alleles and PBC {#s3.7}
--------------------------

Compared with *HLA-DQB1* and *HLA-DPB1* alleles, studies describing *HLA-DRB1* alleles and PBC were more abundant. *HLA-DRB1* alleles were also most extensively studied in the context of a relationship between *HLA-Class II* and PBC. *HLA-DRB1* (*\*01, \*03*, *\*0405*, *\*07*, *\*08*, *\*0801* and *\*0803*) were found to predisposition individuals to PBC, and the pooled results were 1.26 (1.05--1.51), 1.38 (1.16--1.65), 1.43 (1.16--1.76), 2.03 (1.29--3.21) and 1.47 (1.27--1.70), 2.30 (1.76--3.00) and 2.48 (1.60--3.84), 3.23 (2.22--4.70), and 2.64 (1.55--4.51), 3.00 (1.89--4.76), respectively ([Figure **3**](#pone-0079580-g003){ref-type="fig"}; [Table **2**](#pone-0079580-t002){ref-type="table"}). Conversely, *HLA-DRB1* (*\*11*, *\*13*, *\*1101* and *\*1501*) were observed to confer resistance to PBC, and the pooled results were 0.45 (0.33--0.62) and 0.31 (0.27--0.38), 0.41 (0.24--0.68), 0.82 (0.68--0.99), and 0.45 (0.31--0.65), respectively ([Figure **4**](#pone-0079580-g004){ref-type="fig"}; [Table **2**](#pone-0079580-t002){ref-type="table"}). There was no significant heterogeneity in meta-analyses for most *HLA-DRB1* alleles, but high heterogeneity existed in meta-analyses for *HLA-DRB1\*08*, *\*0803* and *\*13*. The subgroup meta-analysis also demonstrated that *HLA-DRB1\*08* is a risk factor for PBC in Caucasian and Asian populations, but significant heterogeneity was observed in subgroup analyses. The subgroup meta-analysis for *HLA-DR\*0803* after stratification by ethnicity indicated that *HLA-DR\*0803* was a risk factor in Asian groups, not Caucasian groups. Also, the subgroup meta-analysis by ethnicity for *HLA-DR\*13* indicated that *HLD-DR\*13* was protective against PBC in Caucasian groups with a smaller heterogeneity.

![Meta-analysis of the studies of *HLA-DRB1\*08*, *\*0801*, *\*0803* and PBC risk.\
a: differences in the number of individuals who carried the *HLA-DRB1* allele, comparing PBC patients and controls. b: differences in the frequency of the *HLA-DRB1* allele between PBC patients and controls.](pone.0079580.g003){#pone-0079580-g003}
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###### Outcome, heterogeneity and publication bias tests for these meta-analyses.

                           Number of                       Heterogeneity           Publication   bias    
  ------------------------ ----------- ------------------- --------------- ------- ------------- ------- -------------------
  *HLA-DR2*                7           0.70 (0.53--0.91)   0.372           7.4%    0.553         0.230   Protective factor
  *HLA-DR5*                8           0.55 (0.39--0.78)   0.268           20.3%   0.902         0.610   Protective factor
  *HLA-DR8*                12          2.82 (1.84--4.30)   0.011           54.8%   1             0.901   Risk factor
  *HLA-DR12*               3           0.40 (0.19--0.86)   0.583           0       0.296         0.207   Protective factor
  *HLA-DR16*               3           0.21 (0.05--0.97)   0.900           0       1             0.124   Protective factor
  *HLA-DR52a*              3           0.60 (0.38--0.95)   0.459           0       1             0.613   Protective factor
  *HLA-DQB1\*02 ^a^*       3           1.40 (1.00--1.97)   0.204           37.2%   1             0.710   Risk factor
  *HLA-DQB1\*0301 ^a^*     3           0.62 (0.48--0.79)   0.468           0       1             0.997   Protective factor
  *HLA-DQB1\*0301 ^b^*     4           0.48 (0.35--0.68)   0.245           27.8%   1             0.558   Protective factor
  *HLA-DQB1\*04 ^a^*       4           2.24 (1.46--3.46)   0.692           0       0.308         0.247   Risk factor
  *HLA-DQB1\*0401 ^b^*     3           1.41 (1.07--1.85)   0.607           0       0.296         0.459   Risk factor
  *HLA-DQB1\*0402 ^a^*     4           3.47 (2.35--5.13)   0.560           0       0.308         0.150   Risk factor
  *HLA-DQB1\*06 ^a^*       3           0.58 (0.39--0.85)   0.433           0       1             0.836   Protective factor
  *HLA-DQB1\*0601 ^b^*     4           1.99 (1.57--2.53)   0.130           46.9%   1             0.778   Risk factor
  *HLA-DQB1\*0602 ^a^*     3           0.61 (0.42--0.87)   0.180           41.8%   0.296         0.229   Protective factor
  *HLA-DQB1\*0602 ^b^*     4           0.53 (0.37--0.75)   0.330           12.6%   1             0.589   Protective factor
  *HLA-DQB1\*0604*         3           0.3 (0.18--0.58)    0.667           0       0.296         0.328   Protective factor
  *HLA-DRB1\*01 ^b^*       6           1.26 (1.05--1.51)   0.134           40.7%   0.452         0.128   Risk factor
  *HLA-DRB1\*03* ^*b*^     5           1.38 (1.16--1.65)   0.920           0       0.221         0.065   Risk factor
  *HLA-DRB1\*0405 ^b^*     4           1.43 (1.16--1.76)   0.749           0       0.734         0.328   Risk factor
  *HLA-DRB1\*07 ^a^*       3           2.03 (1.29--3.21)   0.415           0       1             0.874   Risk factor
  *HLA-DRB1\*07 ^b^*       5           1.47 (1.27--1.70)   0.836           0       0.806         0.083   Risk factor
  *HLA-DRB1\*08 ^a^*       8           2.30 (1.76--3.00)   0.508           0       0.035         0.185   Risk factor
  *HLA-DRB1\*08 ^b^*       6           2.48 (1.60--3.84)   0.035           58.4%   1             0.714   Risk factor
  *HLA-DRB1\*0801 ^a^*     4           3.23 (2.22--4.70)   0.617           0       0.308         0.272   Risk factor
  *HLA-DRB1\*0801 ^b^*     4           2.64 (1.55--4.51)   0.695           0       0.734         0.982   Risk factor
  *HLA-DRB1\*0803 ^b^*     6           3.00 (1.89--4.76)   0.043           56.3%   0.707         0.786   Risk factor
  *HLA-DRB1\*11 ^a^*       5           0.45 (0.33--0.62)   0.729           0       0.462         0.265   Protective factor
  *HLA-DRB1\*11 ^b^*       5           0.31 (0.27--0.38)   0.327           13.6%   0.806         0.190   Protective factor
  *HLA-DRB1\*1101* ^*b*^   4           0.41 (0.24--0.68)   0.336           11.4%   0.734         0.965   Protective factor
  *HLA-DRB1\*13 ^b^*       5           0.82 (0.68--0.99)   0.369           6.6%    0.462         0.225   Protective factor
  *HLA-DRB1\*1501 ^b^*     3           0.45 (0.31--0.65)   0.186           40.6%   1             0.175   Protective factor

a indicated the difference in the number of individuals carried *HLA-DR*, *HLA-DQ*, *HLA-DP* allele between PBC patients and health controls.

b indicated the difference in the frequency of *HLA-DR*, *HLA-DQ* , *HLA-DP* allele between PBC patients and health controls.

![Meta-analysis of the studies of *HLA-DRB1\*11*, *\*1101* and *\*13* and PBC risk.](pone.0079580.g004){#pone-0079580-g004}

HLA haplotype and PBC {#s3.8}
---------------------

Of the 34 studies included, only 6 studies included discussions regarding the association between *HLA* haplotypes and PBC susceptibility \[[@B7],[@B10],[@B20],[@B29],[@B37],[@B46]\]. Due to less overlap among *HLA* haplotypes detected in these 6 studies, a meta-analysis could not be conducted.

Sensitively analysis and assessment of bias {#s3.9}
-------------------------------------------

To assess the influence of each individual study on the overall OR, a sensitivity analysis was conducted by repeating the meta-analysis sequentially excluding one study at a time. Except for *HLA-DRB1\*13*, the estimated pooled ORs were constant and the overall results were relatively stable in the present meta-analysis. The results indicate that the frequency of the *HLA-DRB1\*13* allele in PBC patients is significantly higher than in controls, but this relationship was not observed in individuals who carried the *HLA-DRB1\*13* allele between the PBC group and control group (OR = 0.668, 95%CI: 0.428--1.043; I^2^ = 59.0%, *P* = 0.045). However, after excluding Bittencourt's study \[[@B39]\], the difference in the number of individuals who carried the *HLA-DRB1\*13* allele, comparing PBC patients and controls, achieved significance (OR = 0.553, 95%CI: 0.419--0.729), and this occurred with a lower heterogeneity (I^2^ = 13.8%, *P* = 0.323), supporting the hypothesis that inclusion of this particular study may lead to bias.

As shown in [Table **2**](#pone-0079580-t002){ref-type="table"}, significant heterogeneity (*P* \< 0.1) existed in the three meta-analyses including *DR8* and *HLA-DRB1* (*\*08*, *\*0803*). To investigate this finding, a meta-regression analyses for ethnicity, year of publication, and sample size was performed, and to avoid ecological bias and to limit type I errors, we perform no other exploratory regression analyses, especially for patient-level factors such as sex and age \[[@B48]\]. The meta-regression analysis showed that the major source of the heterogeneity listed in the meta-analyses for *HLA-DR8* and *HLA-DRB1\*08* could not be attributed to ethnicity, year of publication, or sample size (data not shown). However, the results obtained from meta-regression analysis for *HLA-DRB1\*0803* indicated that the year of publication may contribute to findings of heterogeneity, not ethnicity or sample size. After excluding two studies conducted before 2000 \[[@B7],[@B9]\], significant heterogeneity disappeared (I^2^ = 0%, *P* = 0.677). The meta-analyses of *HLA-DRB1\*08* included a study in which PBC patients were a "mixed population", which may explain heterogeneity. However, the heterogeneity in the meta-analysis of *HLA-DRB1\*08* did not decrease after excluding this study (I^2^ = 63.8%, *P* = 0.026) \[[@B42]\].

Publication bias {#s3.10}
----------------

The funnel plot for associations between *HLA Class II* and PBC susceptibility was drawn (data not shown) and publication bias was also measured by formal testing for funnel plot asymmetry using Egger's test and Begg's test. As expected, no significant publication bias was detected ([Table **2**](#pone-0079580-t002){ref-type="table"}).

Disscussion {#s4}
===========

To our knowledge, this is the first study to systemically review and meta-analyze all eligible published data to assess an association between *HLA Class II* and PBC risk. We discovered that common genetic variants of *HLA-Class II* were significantly associated with the development of PBC. A total of 26 *HLA Class II* alleles or antigens were found to be associated significantly with PBC as indicated by our meta-analysis of worldwide published data ([Table **2**](#pone-0079580-t002){ref-type="table"}). Also, 13 of those variants were found to be significant risk factors for PBC including *DR8*, *HLA-DQB1* (*\*02*, *\*04*, *\*0401*, *\*0402* and *\*0601*), and *HLA-DRB1* (*\*01*, *\*03*, *\*07*, *\*08*, *\*0801*, *\*0803* and *\*0405*). Protective factors against PBC were found to include *HLA-DR2*, *DR5*, *DR12*, *DR16*, *DR52a*, *HLA-DQB1* (*\*06*, *\*0301*, *\*0602* and *\*0604*) and *HLA-DRB1* (*\*11*, *\*13*, *\*1501*, and *\*1101*). No consistent conclusion regarding the association of *HLA* haplotypes and PBC risk could be drawn due to the small number of included studies. However, our findings provide important insight into the role of *HLA* class *II* in the immune-pathogenesis of PBC.

A total of 34 studies were included in the present study (1983 to 2012), and 18 of these were determined to be of high quality; 16 were of medium quality; and no study was considered to be of low quality. Therefore, the meta-analysis presented here should reliably clarify which *HLA-Class II* genes may be responsible for PBC.

Our data confirmed that *HLA-DR\*08*, *\*0801*, and *\*0803* were potential risk factors for PBC (corresponding serological type DR8). Previous studies indicated that HLA-DR8 was significantly associated with PBC, with ORs ranging from 2.4 to 3.3 based on the population examined \[[@B49]\]. In contrast, several reports have failed to confirm this association \[[@B30],[@B33]\]. Nevertheless, evidence for this positive association was powerful in the present investigation, with the same direction of effect detected (OR = 2.82, 95%CI: 1.84--4.30). *DRB1\*08* was also observed to have a strong genetic association with PBC among many reports for Caucasian or Asian populations \[[@B8],[@B10],[@B38]\], but other studies failed to show a association between *DRB1\*08* and PBC \[[@B36],[@B41],[@B44]\].

Our work supports the hypothesis that both the number of individuals carrying the *HLA-DRB1\*08* allele and the frequency of the *HLA-DRB1\*08* allele in PBC groups were significantly greater than in control groups. Moreover, the results showed that *HLA-DRB1\*0801* and *\*0803* alleles conferred a predisposition to PBC. *HLA-DRB1\*08*, *\*0801* and *\*0803* and *HLA-DRB1\*01*, *\*03*, *\*0405* and *\*07* were also identified to be risk-conferring alleles, but with relatively weak effects. Although the specific role of *HLA-Class II* risk alleles in PBC remains unclear, HLA molecules encoded by risk alleles such as *DR8*, might preferentially bind and present auto-antigens to T cells and trigger an autoimmune response \[[@B50],[@B51]\]. Further studies are required to elucidate mechanisms by which *HLA-class II* genetic polymorphisms and pathogenesis cooperate in disease states such as PBC.

Strong protective associations between *HLA-DRB1\*11*, *\*1101*, *\*13* and *\*1501* alleles and PBC were observed, and, although these findings have been replicated by several other studies, the data from these reports were inconsistent \[[@B39]-[@B41]\]. We therefore combined quantitative evidence from these studies to offer direct support for the conclusion that *HLA-DRB1\*11*, *\*1101*, *\*13* and *\*1501* alleles had strong protective effects against PBC, which more clearly integrates the relationship between *HLA-class II* and PBC \[[@B14]\]. Previous studies support the finding that *HLA-DRB1\*11* and *\*13* alleles were potent protective factors against some viruses \[[@B52]-[@B54]\]; thus, these *HLA-Class II* alleles may influence resistance to several infectious agents, and the lack of such alleles may lead to the onset of PBC through molecular mimicry of infectious agents. Several studies suggest that infection may be critical to the development of PBC \[[@B4],[@B55],[@B56]\], and our data also support a potential role for infections in PBC etiology.

Data derived from the GWAS of Canadian and Japanese patients indicated that *HLA-DQB1* had the strongest association with PBC. Here, we found 8 *HLA-DQB1* alleles that were associated with PBC and the association of the *HLA-DQB1\*0402* allele with PBC (OR 3.47, 95%CI 2.35--5.13) was strongest among them. All conclusions in 4 studies regarding the association between *HLA-DQB1\*0402* and PBC risk were consistent; this allele is a risk factor for PBC \[[@B10],[@B20],[@B31],[@B38]\]. In contrast, the *HLA-DQB1\*03*, *\*06*, *\*0602*, and *\*0604* alleles conferred protection against PBC. However, the meta-analyses indicated that no *HLA-DPB1* alleles were significantly associated with PBC. Most previous studies have also provided strong evidence for no association between *HLA-DPB1* and PBC. Until now, only two studies have suggested that *HLA-DPB1\*0301* and *\*0501* are associated with PBC, but these were based on relatively small sample populations \[[@B27],[@B34]\]. A recent study from a large Italian cohort indicates that *HLA-DPB1\*0301* was a predisposing risk allele, a finding that is consistent with the previous study of a small German cohort \[[@B57]\]. However, as indicated in previous studies, our data support the finding that most *HLA* associations with PBC could be attributed to specific associations with *HLA-DRB1* and *HLA-DQB1* alleles rather than *HLA-DPB1*.

As mentioned before, the GWAS provided suggestive evidence for a strong association of PBC with *HLA* region polymorphisms. The strength of the association between *HLA-class* alleles and the risk of PBC in our current study was similar to data from other large-scale studies such as GWAS. In Juran's study, 7 *HLA class II* alleles were reported to achieve genome-wide significance including *HLA-DQA1\*0501*, *HLA-DQB1* (*\*0301*, *\*0302* and *\*0402*) and *HLA-DRB1* (*\*0801*, *\*1101* and *\*1501*) \[[@B58]\]. With the exception of *HLA-DQB1\*0302* and *HLA-DQA1\*0501*, six other *HLA-class II* alleles were included in the present study. Data show that roles of these *HLA-class II* alleles in PBC development were quite consistent between Juran's study and our study which suggested that *HLA-DQB1\*0402* and *HLA-DRB1\*0801* contribute to the PBC susceptibility and that conversely, *HLA-DQB1\*0301*, *HLA-DRB1\*1101*, and *HLA-DRB1\*1501* were protective alleles against PBC. Our estimated ORs were also quite similar to Juran's results obtained from three independent large-scale cohorts. Collectively, this information indirectly reflects the accuracy and reliability of the present meta-analysis to study the role of *HLA* class *II* in PBC.

Studies to associate specific *HLA* haplotypes and susceptibility to PBC are scarce and those which exist indicate that several HLA haplotypes were significantly increased or reduced in PBC patients, suggesting that they confer susceptibility or protection to PBC, respectively. For example, the haplotype *HLA-DRB1\*0801-DQB1\*0402* was identified as a risk factor for PBC in Caucasian subjects \[[@B7],[@B34]\], and genes of the haplotype were found to be in linkage disequilibrium in the Caucasian population \[[@B46]\]. Furthermore, the frequency of the *HLA-DRB1\*0801-DQA1\*0401-DQB1\*0402* haplotype was reported to be increased in patients who had progressed to late stages of PBC, but not in those with early stage disease, suggesting that this haplotype may be a specific marker for the overall disease course \[[@B31]\]. We could not perform a meta-analysis to ascertain the association of *HLA* haplotype and PBC risk due to too few relevant original articles. Still, understanding and identifying these haplotype effects may improve research into or clinical treatment of PBC so future studies should be conducted to determine whether specific *HLA* haplotypes are associated with PBC susceptibility.

Our meta-analysis had some limitations. First, we included a wide variety of articles to determine the role of *HLA* class *II* in PBC development, so specific differences within studies may be a potential source of bias. Second, all available studies were published data; unpublished data were not identified. This fact alone suggests that publication bias cannot be absolutely excluded even though no significant publication bias was observed by funnel plot analysis, Egger' test, and Begg's test in the meta-analyses. Next, it is also impossible to completely exclude the influence of confounding factors inherent in these included studies, although subgroup analyses by ethnicity were performed. Other confounders such as age, sex, country, specific technique could not be excluded, and this may explain our findings. Although we performed 32 meta-analyses, 11 of these only included 3 eligible studies. We could not conduct sufficient subgroup meta-analyses after stratification by relevant characteristics in each analysis. Finally, the data regarding PBC and other *HLA-Class II* alleles were extremely sparse and inadequate, limiting our ability to draw conclusions from the meta-analysis.

In summary, our investigations suggest that distinct *HLA* class *II* genetic variants conferred both a predisposition and a resistance to PBC. *HLA-DQB1* (*\*02*, *\*04*, *\*0401*, *\*0402* and *\*0601*) and *HLA-DRB1* (*\*01*, *\*03*, *\*0405*, *\*07*, *\*08*, *\*0801*, and *\*0803*) were identified as risk factors for PBC, whereas *HLA-DQB1* (*\*0301*, *\*06*, *\*0602* and *\*0604*), and *HLA-DRB1* (*\*11*, *\*1101*, *\*13* and *\*1501*) were potent protective factors. Also, *DR8* was identified to be a predisposing factor. These results expand the repertoire of *HLA-Class II* genes with potential roles in PBC pathogenesis, however follow-up biological studies are needed to confirm these associations.
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